All studies
CompletedPhase IIInterventional

EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for locally advanced rectal cancer

The EXCITE study is a clinical trial for adults with locally advanced rectal cancer. This means the cancer is in the rectum (the lower part of the bowel) and has grown into nearby tissues, but has not spread to other parts of the body. Standard treatment often involves radiotherapy and chemotherapy before surgery. In this phase II study, researchers are testing a more intensive treatment. Participants receive a combination of three cancer drugs (cetuximab, capecitabine, and irinotecan) alongside radiotherapy before having their operation. The main goal of the trial is to see if this treatment combination can shrink the tumour (known as downstaging) before surgery. Researchers also want to find out how safe the combination is and monitor any side effects. By shrinking the tumour first, surgeons hope to make it easier to remove the cancer completely.

At a glance

Status
Completed
Phase
Phase II
Sponsor
University College London (UK)
Enrolment target
80
Start
30 Mar 2009
Estimated completion
30 Aug 2011

What is this study about?

Rectal cancer starts in the rectum, which is the final section of the large bowel. When the cancer is 'locally advanced', it means the tumour has grown quite deep into the bowel wall or close to nearby tissues, but it has not spread to distant organs like the liver or lungs. For these tumours, doctors often give treatment before surgery to help shrink the growth and lower the chance of the cancer returning.

The EXCITE trial is testing a combination of radiotherapy and three medicines: capecitabine (a chemotherapy tablet), irinotecan (a chemotherapy drip), and cetuximab (a targeted therapy drip). Targeted therapies work by blocking specific signals that cancer cells need to grow. Combining these drugs with radiotherapy is designed to tackle the tumour from multiple angles before the surgeon operates to remove it.

This study matters because removing a locally advanced tumour completely can sometimes be difficult. If this new combination shrinks the tumour effectively, it could make the operation more straightforward and improve long-term outcomes for patients. Because this is a phase II study, the research team is also carefully watching to see how well patients tolerate having all three drugs alongside radiotherapy.

Key takeaways

  • The EXCITE trial tests three cancer medicines combined with radiotherapy before surgery.
  • It is for adults with locally advanced rectal cancer that has not spread elsewhere.
  • The main aim is to shrink the tumour to make surgery more effective.
  • Doctors are also assessing the safety and side effects of this intensive combination.
  • Joining the trial is voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is designed for adults aged 18 and over who have been diagnosed with locally advanced bowel cancer in the rectum. To take part, scans must show that the tumour is close to or touching the outer layer of tissue around the rectum, or is located very low down near the anus. The cancer must not have spread to distant parts of the body.

Participants need to be in reasonably good general health and able to carry out normal daily tasks. Blood tests must show that your kidneys, liver, and bone marrow are working well enough to safely handle the medicines, and you must be able to swallow tablets.

You cannot take part if you have certain existing bowel conditions, such as Crohn's disease, severe ulcerative colitis, or abnormal passages in the bowel (fistulas), as these can make radiotherapy unsafe. Your hospital doctor can check your scans and medical history to confirm whether this trial is suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with cancer in the rectum (rectal adenocarcinoma).
  3. My cancer is locally advanced, but has not spread to other organs.
  4. I do not have severe bowel conditions like Crohn's disease or severe colitis.
  5. I am well enough to carry out light physical activities and swallow tablets.
  6. My kidney and liver blood tests are in an acceptable range.
Answer every question to see your result.

What does participation involve?

If you join the trial, your treatment will happen in several steps. First, you will take capecitabine tablets at home and visit the hospital to receive irinotecan and cetuximab through a drip into a vein. During this same period, you will attend hospital for daily radiotherapy sessions, usually Monday to Friday for several weeks.

You will have regular blood tests, physical checks, and scans to see how the tumour is responding and to manage any side effects. After finishing the chemotherapy and radiotherapy, you will have a resting period of several weeks to allow your body to recover before having surgery to remove the tumour. After your operation, the research team will continue to check on your health and recovery during routine hospital follow-up visits.

Potential risks and benefits

Taking part may help shrink your tumour before surgery, which could make the operation more successful, though this cannot be guaranteed. The information gathered may also help improve treatments for people with bowel cancer in the future. However, combining three cancer drugs with radiotherapy can cause side effects. These may include loose stools (diarrhoea), skin rashes, feeling sick, tiredness, and an increased risk of infections. Your care team will monitor you closely and provide medicines to help manage these effects. Taking part is entirely your choice, and you can leave the study at any time without it affecting your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Cancer Trials Office
    City only
    London, England

Common questions

What does 'locally advanced' rectal cancer mean?

It means the cancer has grown into the deeper layers of the rectum or nearby tissues, but tests show it has not spread to other organs like the lungs or liver.

How are the medicines given?

Capecitabine is taken as tablets by mouth. Irinotecan and cetuximab are given as liquid infusions (drips) into a vein during hospital visits.

Will I still need an operation?

Yes. The aim of having drug therapy and radiotherapy first is to shrink the tumour so that the surgeon can remove it more cleanly and safely.

What happens if I get severe side effects?

Your medical team will check on you regularly. They can adjust your doses, prescribe treatments to ease symptoms, or pause your treatment if needed to keep you safe.

Do I have to take part in this trial?

No, taking part is completely voluntary. If you choose not to join, your doctor will discuss standard treatment options with you, and your regular NHS care will continue as normal.

How to find out more

Emma Williams

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.